Gerresheimer’s Creditors Grant Reprieve as Strategic Overhaul Intensifies

Düsseldorf-based packaging specialist Gerresheimer has secured a crucial financial lifeline from its creditors, buying time to navigate a severe accounting crisis while pushing ahead with a strategic refocus. In a decisive show of conditional support, 96% of holders of the company’s €870 million in Schuldschein loans agreed to extend the deadline for submitting its audited 2025 financial statements to September 30, 2026.

This move is far from routine. Parallel agreements with banking partners suspend key debt covenants, specifically those related to leverage ratios, until the end of the third quarter of 2026. The sweeping approval effectively removes immediate pressure from the company’s capital structure, providing a buffer to complete internal investigations and balance sheet remediation.

The backdrop to this creditor forbearance is a serious financial scandal. Germany’s financial watchdog, BaFin, is examining past balance sheets, with potential write-downs of up to €240 million on the table. The audit supervisor is also investigating KPMG, which had issued an unqualified audit opinion on the previous annual report. The company aims to publish the audited consolidated financial statements, which will quantify the exact scale of the accounting errors, in June.

Operationally, management is attempting to project business-as-usual confidence. The company states that the 2026 financial year is progressing within expectations, with solid order intake. Ambitious targets are still in place: Gerresheimer is aiming for an EBITDA margin of 18-19% on expected revenue of €2.3 to €2.4 billion this year, which would translate to an operating profit exceeding €400 million.

This creates a stark contrast with the company’s current market valuation of approximately €750 million. Analysts suggest that successfully cleaning up the balance sheet while hitting these margin goals could create a significant valuation gap, presenting a potential case for a re-rating of the stock.

Should investors sell immediately? Or is it worth buying Gerresheimer?

Simultaneously, Gerresheimer is advancing a strategic pivot. The company recently rejected an unsolicited takeover approach from US competitor Silgan Holdings, signaling a commitment to an independent path. Its focus is now on the planned sale of its US subsidiary Centor, which is being reviewed by a double-digit number of interested parties, with a transaction expected this year.

On the innovation front, the group is promoting its LeneX UltraGuard® technology to strengthen its position in specialty packaging for the pharmaceutical and veterinary medicine sectors.

Shareholder sentiment has been volatile. The stock, currently trading around €21.80, has lost about half its value over the past year. However, it has recovered roughly 40% from its 52-week low of €15.57 hit in February and recently posted a weekly gain of over 23%. While the share price has crossed above its 50-day moving average—a short-term technical positive—it remains nearly 25% below its 200-day average, underscoring a persistent longer-term downtrend.

The coming months present a critical sequence of events. The June release of the audited accounts will define the scale of the challenge, while the sale of Centor is a key step in the strategic overhaul. The ultimate test will come in September 2026: if Gerresheimer can deliver transparency on its balance sheet issues and confirm its operational targets, it may lay the groundwork for a more sustained recovery.